Literature DB >> 2572269

Development of an ELISA to detect early local relapse of colorectal cancer.

L G Durrant1, H Jones, N C Armitage, R W Baldwin.   

Abstract

The Y haptenic blood group determinant is expressed on the cells of malignant gastrointestinal tumours and on the normal gastrointestinal epithelium of individuals who can secrete blood group antigens. an enzyme-linked immunosorbent assay incorporating the high affinity biotin-avidin interaction was developed to measure the serum levels of antigens bearing the Y hapten in patients with colorectal cancer. The specificity of the assays was between 88 and 93% and the sensitivity in detecting extensive disease was between 24 and 34%. However, up to 67% of patients with local or abdominal recurrent disease secreted antigens expressing the Y hapten, whereas only 30% of patients with overt hepatic metastases secreted a similar antigen. Recognition of antigens bearing the Y hapten may therefore be useful in detecting early local relapse of colorectal cancer when a second operation to excise the recurrence may be possible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572269      PMCID: PMC2247095          DOI: 10.1038/bjc.1989.308

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Carcinoembryonic antigen and recurrent colorectal cancer.

Authors:  J Northover
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

2.  A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains.

Authors:  A Brown; T Feizi; H C Gooi; M J Embleton; J K Picard; R W Baldwin
Journal:  Biosci Rep       Date:  1983-02       Impact factor: 3.840

3.  Mouse monoclonal antibody F-3 recognizes the difucosyl type-2 blood group structure.

Authors:  K O Lloyd; G Larson; N Strömberg; J Thurin; K A Karlsson
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

4.  The use of avidin-biotin interaction in immunoenzymatic techniques.

Authors:  J L Guesdon; T Ternynck; S Avrameas
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

5.  Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma.

Authors:  M A Herrera; T M Chu; E D Holyoke
Journal:  Ann Surg       Date:  1976-01       Impact factor: 12.969

6.  Differential expression of difucosyl type 2 chain (LeY) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas.

Authors:  K Abe; S Hakomori; S Ohshiba
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

7.  Association of antigen expression and DNA ploidy in human colorectal tumors.

Authors:  L G Durrant; R A Robins; N C Armitage; A Brown; R W Baldwin; J D Hardcastle
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

8.  The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer.

Authors:  C B Wood; J G Ratcliffe; R W Burt; A J Malcolm; L H Blumgart
Journal:  Br J Surg       Date:  1980-01       Impact factor: 6.939

9.  Role of carcinoembryonic antigen in detection of asymptomatic disseminated disease in colorectal carcinoma.

Authors:  I G Finlay; C S McArdle
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-16

10.  Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumours and normal adult tissues.

Authors:  A Brown; I O Ellis; M J Embleton; R W Baldwin; D R Turner; J D Hardcastle
Journal:  Int J Cancer       Date:  1984-06-15       Impact factor: 7.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.